Manufacturing


  • Helen Sabzevari header
    Image attribution tooltip
    Permission granted by Precigen
    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Helen Sabzevari, an immunotherapy pioneer

    Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

    By Oct. 27, 2023
  • spilling cough syrup
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 recent FDA adcomm rejections — and why they matter

    Decisions that could spell doom for drugs in development and already on the shelves.

    By Sept. 29, 2023
  • test tube gene Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Cell and gene therapies

    How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

    By PharmaVoice staff
  • CSL Seqirus influenza vaccine being prepared in the lab.
    Image attribution tooltip
    Permission granted by CSL Seqirus
    Image attribution tooltip

    Finding the right flu vaccine is hard. Getting people to take it is harder.

    Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.

    By Aug. 30, 2023
  • Pills of varying colors lay against a blue background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’

    FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages. 

    By Karissa Waddick • Aug. 25, 2023
  • vaccine vial
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s rare disease rush

    Biogen’s acquisition of Reata Pharmaceuticals is the latest in a string of high-dollar rare disease deals over the last few months. What does it mean for industry?

    By , Karissa Waddick • Aug. 14, 2023
  • An AbbVie sign is seen on a building at the pharmaceutical company's U.S. headquarters.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    Biosimilar makers split strategies in bid to take on top-selling Humira

    In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.

    By Jonathan Gardner • July 26, 2023
  • Pharma vials
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A

    As biologics boom, here’s how manufacturers are keeping up

    Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.

    By July 19, 2023
  • two lab techs pipette
    Image attribution tooltip
    Adene Sanchez via Getty Images
    Image attribution tooltip

    Boosting the cell and gene therapy workforce with a skilled, localized approach

    Experts provide a roadmap for how the industry can work with academia to ensure a robust talent pipeline for the burgeoning field.

    By Karissa Waddick • June 15, 2023
  • Money squeeze
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Drugmakers feel the squeeze as cost pressures mount

    Supply chain challenges have eased — but now inflation and manufacturing complexity are triggering a new sense of urgency to bring costs down.

    By Kelly Bilodeau • June 5, 2023
  • Silhouette of business people negotiating at meeting table
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Strangers in a strange land: 8 unlikely companies making plays in pharma

    How these consumer and service companies are tapping into major trends in the biopharma industry.

    By Karissa Waddick • May 22, 2023
  • Trish Hurter on horseback
    Image attribution tooltip
    Permission granted by Patricia Hurter
    Image attribution tooltip
    Profile

    A day in the life of a pharma exec: Lyndra’s Patricia Hurter

    How the CEO starts each day with a ride on one of her horses, reduces daily meetings and uses her network to get through crises like the SVB Bank collapse.

    By May 17, 2023
  • blood sample tubes
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Where one unicorn struggled, another biotech is aiming for a diabetes win

    Intarcia looked poised to break into a lucrative diabetes implant market but has been dogged by safety issues — now Vivani thinks it’s found a way to succeed.

    By Kelly Bilodeau • April 10, 2023
  • A science lab with no workers
    Image attribution tooltip
    alvarez via Getty Images
    Image attribution tooltip

    Staff shortages cause slowdowns in booming cell and gene therapy market

    New reports highlight the need for more targeted biotech education curriculums to shore up a sustainable workforce.

    By Karissa Waddick • April 3, 2023
  • Glass vials with orange caps sit on a pharmaceutical factory production line.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

    The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.

    By Jan. 9, 2023
  • crystal ball 2023
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion

    The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

    A preview of the top trends on the minds of industry and market leaders for the new year.

    By Jan. 3, 2023
  • Bill Mezzanotte headshot
    Image attribution tooltip
    Permission granted by CSL
    Image attribution tooltip
    Q&A

    A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’

    The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug. 

    By Dec. 6, 2022
  • IV infusion
    Image attribution tooltip
    Amornrat Phuchom via Getty Images
    Image attribution tooltip

    While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

    Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

    By Nov. 8, 2022
  • In the distance, exhaust plumes billow over seven power plants. The reflection of the power plants can be seen in a lake.
    Image attribution tooltip
    Sean Gallup / Staff via Getty Images
    Image attribution tooltip

    How Europe’s energy crisis is impacting pharma

    Inflationary pressures and rising energy costs could further expedite the movement of generics manufacturing from Europe to Asia if governments don’t step in.

    By Karissa Waddick • Nov. 2, 2022
  • Graphic of blue and yellow shapes on grey background
    Image attribution tooltip
    Permission granted by Phil Inc.
    Image attribution tooltip
    Sponsored by Phil, Inc.

    Developing a channel strategy that optimizes gross to net

    Today, pharma manufacturers face unprecedented GTN challenges. To unlock sustainable brand growth, a value-aligned channel strategy is pivotal.

    Oct. 31, 2022
  • Doug langa head shot
    Image attribution tooltip
    Permission granted by Doug Langa
    Image attribution tooltip

    Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots

    The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.

    By Oct. 25, 2022
  • missing target
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 impactful drug trial failures from the last year

    Major recent trial flops and what they mean for companies, patients and the industry.

    By Oct. 19, 2022
  • A wood cutout of a person wearing a tie, holding a telescope and standing on a set of four arrows of differing sizes.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Making Moves

    C-suite shake-ups at 23andMe, Moderna signal new stages of growth

    With their latest personnel moves, these life sciences companies are preparing for major business shifts.

    By Karissa Waddick • Oct. 5, 2022
  • cell therapy infusion
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    It’s electric — speeding up the cell therapy process for scalability

    To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

    By Alexandra Pecci • Oct. 4, 2022
  • Colonies of bacteria in MacConkey agar
    Image attribution tooltip
    Md Saiful Islam Khan via Getty Images
    Image attribution tooltip

    Feds could soon bring COVID-style fight to superbug threat

    COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

    By Karissa Waddick • Sept. 13, 2022
  • cell therapy infusion
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    4 ways to nail the launch of your cell therapy

    A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

    By Aug. 10, 2022